NCT07154069View on ClinicalTrials.gov

Adaptive Immunotherapy for Nasopharyngeal Carcinoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

802

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2031

Study Completion Date

September 30, 2033

Conditions
Nasopharyngeal Cancinoma (NPC)
Interventions
RADIATION

Radical radiotherapy of nasopharynx and neck

Radical radiotherapy of nasopharynx and neck

DRUG

Capecitabine

Adjuvant metronomic capecitabine (650 mg/m² twice daily) for one year

DRUG

Concurrent chemoradiotherapy (cCRT)

Concurrent chemoradiotherapy

DRUG

Toripalimab

Adjuvant Toripalimab (240mg day1, Q3W )

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER